Lower cognitive performance in healthy G2019S LRRK2 mutation carriers. - Wikidata - awgldk - TriplyDB

Lower cognitive performance in healthy G2019S LRRK2 mutation carriers.

Lower cognitive performance in healthy G2019S LRRK2 mutation carriers.

http://www.wikidata.org/entity/Q36198611

about

Progressive degeneration of human neural stem cells caused by pathogenic LRRK2 Parkinson Disease and Dementia.The neurobiological basis of cognitive impairment in Parkinson's disease.The spectrum of cognitive impairment in Lewy body diseases Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers.Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene Increase in the Inflammatory Marker GlycA over 13 Years in Young Adults Is Associated with Poorer Cognitive Function in Midlife.Heterozygous deletion of the LRFN2 gene is associated with working memory deficits.Hyperbaric oxygen can induce neuroplasticity and improve cognitive functions of patients suffering from anoxic brain damage.LRRK2: cause, risk, and mechanism.Cognitive Performance Patterns in Healthy Individuals with Substantia Nigra Hyperechogenicity and Early Parkinson's Disease Cognitive decline in Parkinson disease.Human LRRK2 G2019S mutation represses post-synaptic protein PSD95 and causes cognitive impairment in transgenic mice A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers.Association between Parkinson's disease and G2019S and R1441C mutations of the LRRK2 gene.Clinical Features of LRRK2 Carriers with Parkinson's Disease.White matter correlates of cognitive domains in normal aging with diffusion tensor imaging Hyperbaric Oxygen Therapy Can Induce Angiogenesis and Regeneration of Nerve Fibers in Traumatic Brain Injury Patients.Association of Polygenic Risk Score With Cognitive Decline and Motor Progression in Parkinson Disease.Cognitive changes in prodromal Parkinson's disease: A review.DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease.Intact working memory in non-manifesting LRRK2 carriers--an fMRI study.Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation.Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism.Substantia nigra hyperechogenicity is related to decline in verbal memory in healthy elderly adults.Fasting plasma glucose in young adults free of diabetes is associated with cognitive function in midlife.Hyperbaric oxygen may induce angiogenesis in patients suffering from prolonged post-concussion syndrome due to traumatic brain injury.Pleiotropic Effects of Variants in Dementia Genes in Parkinson Disease.Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation.Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?Cognition among individuals along a spectrum of increased risk for Parkinson's disease

P2860

Q24301070-CB17991E-F29A-4807-83E5-7EA307228A57 Q30248574-A21A7CE4-4FFD-42BB-A50A-204248AA69DF Q33724698-6F016DC3-825D-4AB4-9826-687B76B88F80 Q34019751-ADF7BE87-7DAC-41EB-9EA3-27C19D57E5AE Q35106295-262A460B-2DD1-45D6-A93C-2FD8449FB8C6 Q35772821-DAACAAF5-C2CB-4319-9E3E-3A7EA7D11FA5 Q35787860-2056BA44-96BF-4098-8AE6-71D2A0C3B851 Q36902733-4B68F3AF-4E0A-497B-BFE6-6ACB4B0DD277 Q37044137-BF5E536E-DAD6-4463-97CE-6697BEC38A3A Q37635000-3D40B92A-A8F3-4475-9AD7-811792449CA7 Q38384109-4A086DFA-5C77-4411-A9F3-D3EC8066DE65 Q38751099-FCF06B5B-66B1-4EB4-BF09-CFAC85674BC4 Q38795375-C484338F-6C01-4C9C-AF62-B0AB7E7CFCFA Q38843010-DCD6CC18-373F-4BBA-B1D5-7C281A54E211 Q38936883-FAD1ECD5-F686-4D0B-A7B5-264F7D74E6E8 Q39206423-317A8534-D6A9-4DE7-ADB2-32EAA00D2A01 Q41215485-7A649A21-366B-4733-A8A8-86FDC4DDC920 Q43260567-3801560B-FE3C-4FBA-BD32-B4029377E58E Q47555107-788C7C25-AB4A-4B5F-9FCD-F06F9BDCAAC2 Q47860019-22B062CC-F51C-4BCD-9460-7B3E3330592F Q47907932-0A34D89B-2371-4734-9FC7-272B3E76EB05 Q47972063-6FBFDE2E-996B-4F33-B8BE-F8EFCB0A9FF1 Q48192270-EE9F7B77-82C2-42DD-B52D-D293E402D8DA Q48248911-0D5F165C-8EC0-4E26-94A6-92885CD6A105 Q48878610-E1B48AA1-60BA-4943-91BA-B3E168113F0F Q50000495-4E287424-F6DE-4057-BB51-3091784C3DD0 Q52147745-A7574625-20EA-40AB-9C90-21AC19AD6BAB Q53397478-11BF86B4-C0F2-40A6-B6BE-4081E686FE92 Q54403187-9A077AFB-DD32-4EFB-8C11-2E0E6C40194C Q54982491-A20393F2-8167-400F-A9D4-B755C1A2311A Q57168544-600A3870-EC4F-4D17-885E-5D2532550984

P2860

Lower cognitive performance in healthy G2019S LRRK2 mutation carriers.

http://www.wikidata.org/entity/Q36198611

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Lower cognitive performance in healthy G2019S LRRK2 mutation carriers.

@ast

Lower cognitive performance in healthy G2019S LRRK2 mutation carriers.

@en

type

label

Lower cognitive performance in healthy G2019S LRRK2 mutation carriers.

@ast

Lower cognitive performance in healthy G2019S LRRK2 mutation carriers.

@en

prefLabel

Lower cognitive performance in healthy G2019S LRRK2 mutation carriers.

@ast

Lower cognitive performance in healthy G2019S LRRK2 mutation carriers.

@en

P1433

Q36198611-50C1C702-97DE-4DCF-9E59-FCE4D32A63D4

P1476

Q36198611-45244210-E4A0-4857-9579-A01F8771B891

P2093

Q36198611-0434DEB3-075D-42F2-9011-799BA1C06A6E

Q36198611-3A5B417B-0068-4769-842E-00C67EBB1F7F

Q36198611-4B6ABE13-38B4-42AF-AA64-2B5A34D73202

Q36198611-BC6AF21C-463D-4794-B1BA-317CEF6A881D

Q36198611-DA8E336B-50BD-433B-A281-6D2E5AF85127

Q36198611-DCE25639-8A2E-4041-8012-9203FDD3039E

Q36198611-E8B5A1B0-3FF3-418F-A5D0-FDA4207B49EF

P2860

Q36198611-0684FC49-0ADF-4C70-BE02-4F06538FC9D3

Q36198611-0CD4F1A3-8B9B-4BBA-B66B-77CC549F4CBE

Q36198611-26655F3F-977A-4B6D-A9BB-BF503E7CB299

Q36198611-37BAB7D5-D0F5-4A84-B51D-C7EDEE0B2C56

Q36198611-395E4DC2-70ED-40A8-B518-647C0FF1A73B

Q36198611-3A84DE92-AC6C-45CD-830A-6B51B0CF64AD

Q36198611-3E30D2E3-6C6F-42DD-B867-36063E2028ED

Q36198611-3FC87DA4-2A8C-4FCE-BA88-26EC5C6B1C31

Q36198611-5084965B-B4D5-48A6-BCF7-8EB5F2FD6191

Q36198611-538A7EE4-E40C-456F-9468-AB8189A7AC70

P304

Q36198611-46CD4CC6-5B9A-46A7-A64C-3DEC43613AD1

P31

Q36198611-4D5B5566-6A1A-4B8F-A7D8-20BD9220E49A

P356

Q36198611-CFEA9AB5-11CA-4F71-9ECB-D1040645A7B7

P407

Q36198611-88733457-F7DF-4F43-8162-AD5C042431DE

P433

Q36198611-5B496295-970F-4A6F-8630-D723AF670BDE

P478

Q36198611-985C7F01-0E1D-4745-8DDC-7E3FE9FFA9D6

P50

Q36198611-025A2AB5-5290-49DC-A0B7-4E4C17F57BE5

Q36198611-07DD2845-DF58-49EC-8CE9-A319BC1F1E42

Q36198611-447A1BC0-A916-4D53-A065-2D10BA32A7B7

P577

Q36198611-CEFC0709-CC53-4840-8750-1B0B9A4F10E8

P698

Q36198611-CA117058-64D4-4D5B-B26E-E220B68DD209

P932

Q36198611-CCC8A117-5C58-474E-8019-2ADB2FEC8B48

P356

WNL.0B013E3182684646

P1433

P1476

Lower cognitive performance in healthy G2019S LRRK2 mutation carriers.

@en

P2093

Anat Mirelman

http://www.w3.org/2001/XMLSchema#string

Avner Thaler

http://www.w3.org/2001/XMLSchema#string

Ely Simon

http://www.w3.org/2001/XMLSchema#string

Karen Marder

http://www.w3.org/2001/XMLSchema#string

LRRK2 Ashkenazi Jewish Consortium

http://www.w3.org/2001/XMLSchema#string

Susan Bressman

http://www.w3.org/2001/XMLSchema#string

Tanya Gurevich

http://www.w3.org/2001/XMLSchema#string

P2860

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment

Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations.

Premotor Parkinson's disease: clinical features, detection, and prospects for treatment.

Depression rating scales in Parkinson's disease: critique and recommendations.

The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?

Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers

Utility of the NeuroTrax computerized battery for cognitive screening in Parkinson's disease: comparison with the MMSE and the MoCA.

A common cognitive profile in elderly fallers and in patients with Parkinson's disease: the prominence of impaired executive function and attention.

P304

1027-1032

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0B013E3182684646

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

79

http://www.w3.org/2001/XMLSchema#string

P50

Avi Orr-Urtreger

P577

2012-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22914834

http://www.w3.org/2001/XMLSchema#string

P932

3430708

http://www.w3.org/2001/XMLSchema#string